Rachel S. Riley

Rachel S. Riley

Auto-generated profile, based on publicly available information

Rachel S. Riley

Department of Biomedical Engineering, Henry M. Rowan College of Engineering, Rowan University, 201 Mullica Hill Rd, Glassboro, NJ 08028, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
RRRachel S. Riley
Rachel S. Riley
MKMeghana V. Kashyap
Meghana V. Kashyap
MBMargaret M. Billingsley
Margaret M. Billingsley
BWBrandon White
Brandon White
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
MMMichael Mitchell
Michael Mitchell
Lipid nanoparticles deliver mRNA to mouse fetuses, which may ultimately enable in utero therapy to treat fetal genetic diseases.


1 January 2020 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
CFChristian G. Figueroa-Espada
Christian G. Figueroa-Espada
SHSamuel Hofbauer
Samuel Hofbauer
MMMichael Mitchell
Michael Mitchell
RRRachel S. Riley
Rachel S. Riley

27 April 2018 in Nano Letters
Verified
Journal Article
Closed access
RRRachel S. Riley
Rachel S. Riley
MDMegan N. Dang
Megan N. Dang
MBMargaret M. Billingsley
Margaret M. Billingsley
BABaxter Abraham
Baxter Abraham
LGLars Gundlach
Lars Gundlach
EDEmily S. Day
Emily S. Day

1 April 2024 in Bioactive Materials
Verified
Journal Article
Open access
RYRachel E. Young
Rachel E. Young
KNKatherine M. Nelson
Katherine M. Nelson
SHSamuel I. Hofbauer
Samuel I. Hofbauer
TVTara Vijayakumar
Tara Vijayakumar
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RRRachel S. Riley
Rachel S. Riley
Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to specific tissues compared to mRNA with no carrier platform. However, LNPs are only in the beginning stages of development for safe and effective mRNA delivery to the placenta to treat placental dysfunction. Here, we develop LNPs that enable high levels of mRNA delivery to trophoblasts in vitro and to the placenta in vivo with no toxicity. We conducted a Design of Experiments to explore how LNP composition, including the type and molar ratio of each lipid component, drives trophoblast and placental delivery. Our data revealed that utilizing C12-200 as the ionizable lipid and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as the phospholipid in the LNP design yields high transfection efficiency in vitro. Analysis of lipid molar composition as a design parameter in LNPs displayed a strong correlation between apparent pKa and poly (ethylene) glycol (PEG) content, as a reduction in PEG molar amount increases apparent pKa. Further, we present one LNP platform that exhibits the highest delivery of placental growth factor mRNA to the placenta in pregnant mice, resulting in synthesis and secretion of a potentially therapeutic protein. Lastly, our high-performing LNPs have no toxicity to both the pregnant mice and fetuses. Our results demonstrate the feasibility of LNPs as a platform for mRNA delivery to the placenta, and our top LNP formulations may provide a therapeutic platform to treat diseases that originate from placental dysfunction during pregnancy.

22 April 2022 in Molecular Therapy
Verified
Journal Article
Open access
RYRachel E. Young
Rachel E. Young
SHSamuel I. Hofbauer
Samuel I. Hofbauer
RRRachel S. Riley
Rachel S. Riley